Pfizer Picks a Local Target, Sermo Meets Satellite Radio, and the Rest of the Recent Deals

11/19/07

Even though last week was a short one, there was so much wheeling and dealing that I wound up doing an extra roundup on Wednesday. But wait, there was more… Here are the deals that were announced since last we rounded up.

—Boston-based RNAi therapeutics startup Dicerna finalized its $13M Series A financing led by Oxford Bioscience Partners and Skyline Ventures.

—Cambridge, MA’s Verenium (NASDAQ: VRNM), a biofuel firm formed this summer by the merger of Cambridge’s Celunol and San Diego’s Diversa, filed a shelf registration statement covering the potential issuance of up to $150 million of stock, debt securities, or warrants.

—Point-of-care diagnostics maker Inverness Medical Innovations (AMEX: IMA) of Waltham, MA, priced a $738 million secondary public offering of stock. The deal was nearly double the size of what Inverness originally announced.

—Woburn, MA-based BioVex completed a Series E financing round, led by Triathlon Medical Ventures, and a venture debt transaction with Oxford Finance Corporation and Silicon Valley Bank. Combined, the two deals are worth $35 million.

—Sermo, a Cambridge, MA. startup that runs a physicians-only social network, partnered with Chicago’s ReachMD XM Satellite Radio, a medical broadcaster. Under the agreement (financial terms of which were not released), ReachMD listeners will be able to discuss the channel’s broadcasts on Sermo, and Sermo users will be able to access certain ReachMD segments directly from the site.

—Boston’s Backchannelmedia completed a $9.5 million seed funding round. The firm’s technology lets TV viewers tag or bookmark pop-up ads during shows, as Wade explained in a profile of Backchannelmedia on Friday.

—While observers wait to see if Pfizer (NYSE: PFE will make a grab for Biogen Idec or Genzyme, the pharmaceutical giant instead announced that it’s acquiring Wellesley, MA-based vaccine-maker Coley Pharmaceutical Group (NASDAQ: COLY) for $164 million.

By posting a comment, you agree to our terms and conditions.